PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, announced today that it will shortly commence distributing Meloxicam, the generic equivalent of Boehringer Ingelheim’s Mobic®. Sales of Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis, were approximately $1.4 billion for the twelve months ended November 2006, according to Wolters Kluwer.
